6535.TWO

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$177M	+757.9%	$-2.77	$-2.77–$-2.77	—	1
2027	$32M	-81.9%	$-2.42	$-2.42–$-2.42	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-10	$-0.38	$-0.97	-154.5%
2026-05-11	$-0.72	$-0.72	+0.0%
2026-02-23	$-0.51	$-0.34	+33.3%
2025-11-12	$-0.50	$-0.20	+60.0%
2025-08-08	$-0.54	$-0.89	-64.8%
2025-05-05	$-0.48	$-0.63	-31.3%
2025-03-03	$-0.47	$-0.90	-93.5%
2024-11-11	$-0.51	$-1.40	-174.5%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
6535.TWOLumosa Therapeutics Co., Ltd.	$74.60	-0.80%	$12.5B	—
4147.TWOTaiMed Biologics Inc.	$60.80	+2.01%	$16.5B	—
4728.TWOSunmax Biotechnology Co., Ltd.	$392.00	-0.76%	$21.3B	—
4743.TWOOneness Biotech Co., Ltd.	$44.20	+1.61%	$21.2B	—
6541.TWTanvex BioPharma, Inc.

Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.

www.lumosa.com.tw

Employees: 36
IPO / List date: Jul 16, 2015
HQ: TW

Held by traders on TradeandTell

No one on the platform currently holds 6535.TWO.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 6535.TWO as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 6535.TWO yet.